Shohei Koyama

The paper identifies NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer, linking its expression to response to enfortumab vedotin and checkpoint inhibitors.

This paper identifies soluble CD155 as a systemic checkpoint that suppresses DNAM-1 signaling, leading to resistance to immune checkpoint inhibitors, and shows that an anti-sCD155 antibody can reprogram this signaling to enhance antitumor immunity.

This paper develops a novel MICA/B-targeting antibody that enhances NK cell activity and shows therapeutic efficacy in KRAS LKB1 mutant lung cancer models.